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What Transplants Can Learn from Fetuses
Rejection of transplants is immunologic in nature and this
applies also for skin transplants. Thus transplant rejection can
be prevented by immunosuppression, however, this is
associated with general side effects. This problem would be
solved if the immune system could be inhibited only in the area
of the transplant, leaving the rest of the body immunocompe-
tent. Fetuses represent a kind of allograft but usually are not
rejected during pregnancy. This may be due to the expression
of indoleamine 2,3-dioxygenase (IDO) in the placenta. IDO is
a tryptophan catabolizing enzyme and thus generates a
tryptophan-deficient environment in the placenta. Immune
cells desperately need tryptophan to proliferate. Conse-
quently, proliferation and thus infiltration of lymphocytes and
macrophages into the placenta is inhibited by IDO. Thus, IDO
functions as a local immunosuppressive factor in the placenta,
preventing immunological rejection of the fetal allograft.
Seeking a possible way of making a non-rejectable skin
substitute, Li and co-workers postulated that in analogy to
pregnancy, expression of IDO by dermal fibroblasts could
function as a local immunosuppressive factor to prevent
immune rejection. By adenoviral transfection, IDO-expressing
dermal fibroblasts were generated and co-cultured with
different types of immune cells such as CD4þ Jurkat cells,
THP-1 monocytes, human peripheral blood mononuclear cells,
CD4þ , CD8þ and B cell-enriched lymphocytes. After 3 days
the vast majority of the immune cells underwent apoptosis, as
demonstrated by FACS analysis and TUNEL staining. IDO-
mediated damage of immune cells was restored by the addition
of tryptophan and to a lesser extent by an IDO inhibitor. In
contrast, keratinocytes, endothelial cells and fiboblasts them-
selves were remarkably resistant to the tryptophan-deficient
environment generated by IDO-overexpressing cells.
Admittedly, several problems need to be solved, e.g.,
stability of transfection before this approach will enter
practical application and become therapeutic reality. Never-
theless, the demonstration of the differential sensitivity
between immune cells and skin cells supports the concept
of the benefit of a local immunosuppressive factor such
as IDO in the development of non-rejectable skin substitutes.
These could not only serve as wound coverages, but also as
a rich source of wound-healing promoting factors (p 953).
Histamine—Bridging the Gap Between
Acute and Chronic Atopic Dermatitis
Atopic dermatitis is an inflammatory skin disease charac-
terized by intensely pruritic acute and chronic eczematous
lesions. Different pathogenic mechanisms are responsible
for the induction of the acute exudative and the chronic
eczematous lesions. While in the first case eosinophils,
mast cells, interleukin-4, interleukin-5, IgE and histamine
are the key players, in the chronic stage T lymphocytes,
macrophages IL-2, interferon-g give the tone. The mechan-
isms which are responsible for the transition from the acute
into the chronic stage are less clear. In the report in this
issue, Kanda and Watanabe provide some evidence that
histamine might be involved in this process (p 863).
The production of granulocyte–macrophage colony-
stimulating factor (GM–CSF) in keratinocytes is highly
related to the chronicity of atopic dermatitis. In atopic skin
lesions, GM–CSF is overproduced by keratinocytes. GM–
CSF promotes the migration, survival and antigen-present-
ing capacity of epidermal Langerhans cells and dermal
dendritic cells, and supports the differentiation into dendritic
cells from peripheral blood precursors. In addition, GM–
CSF also supports the survival of eosinophils and mono-
cytes/macrophages and enhances the proliferation of
keratinocytes, thus contributing to the perpetuation of
inflammation and epidermal hyperplasia in the chronic
lesions of atopic dermatitis. To better elucidate the relation
between acute and chronic atopic dermatitis, Kanda and
Watanabe examined the effect of histamine, a mediator of
acute lesions, on the release of GM–CSF by keratinocytes.
Histamine increased GM–CSF secretion and mRNA level in
keratinocytes. Several signalling pathways appear to be
involved in this process since histamine activated protein
kinase Ca, and the transcription factors AP-1 and NF-kB.
Induction of GM–CSF by histamine was completely abol-
ished by H1 antagonists and protein kinase C inhibitors.
Thus, these results indicate that mast cell-derived
histamine may contribute to GM–CSF overproduction by
keratinocytes in atopic skin lesions. Since GM-CSF is
known to enhance per se the production of c-Jun and c-Fos
and to promote AP-1 transcriptional activity, keratinocyte-
derived GM–CSF may further promote its own transcription
via AP-1 and thus may perpetuate skin inflammation,
indicating a positive feedback loop and causing chronicity
of the lesions. Hence, histamine may not only be involved in
the manifestation of the acute lesions of atopic dermatitis
but in parallel determine the course for chronicity via
induction of the secretion of GM–CSF. Thus, histamine
may be one of the mediators bridging the gap between the
acute and the chronic form of atopic dermatitis.
Pathogenesis of Psoriasis—the Cytokine
Hunting Continues
Psoriasis is regarded as a type-1 T cell-mediated, chronic
inflammatory skin disease. Several cytokines exhibit the
capacity to induce a type-1 T cell response. Hence, it is
tempting to postulate that these mediators may be involved
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in the pathogenesis of psoriasis. Many cytokines have been
suspected, many were investigated, but all tested so far
turned out to be innocent. Litjens and co-workers add
another interleukin, IL-12, to the list of mediators which
obviously cannot be blamed to be responsible for causing
psoriasis (p 923).
IL-12 is a heterodimeric cytokine consisting of two
chains p35 and p40. Only the heterodimer p70 is biologi-
cally active. IL-12p70 preferentially produced by antigen
presenting cells promotes the development of type-1 T
cells. The authors of this study investigated whether blood
cells from psoriatics release higher levels of IL-12 upon
stimulation with lipopolysaccharide (LPS). Blood cells of
psoriasis patients did not produce more IL-12p70 or
IL-12p40 upon optimal stimulation with LPS than cells of
healthy volunteers, however. No association was detected
between the severity of the disease and the LPS-stimulated
IL-12p70 or IL-12p40 production by blood cells. Further-
more, no difference between the two types of onset of
psoriasis with respect to the LPS-stimulated production of
IL-12p70 and IL-12p40 by blood cells was observed. Blood
cells of psoriatics, however, released more IL-12p70/IL-
12p40 than blood cells of healthy volunteers upon stimula-
tion with suboptimal doses of LPS, indicating that psoriatic
cells are ‘‘primed to a type-1 immune response’’ or more
susceptible to LPS. In addition, the frequencies of the
various IL12B promoter genotypes in psoriasis patients
were not different from that reported for healthy volunteers.
Likewise, the frequencies of the various IL12B promoter
genotypes did not differ between the two types of onset of
psoriasis.
Psoriasis is a multifactorial disease and its pathogenesis
appears to be extremely complex, involving several different
factors including genetics, environmental factors, etc. Thus
it is not surprising that a single cytokine may not give the
answer to the pathogenetic secrets of this disease. Based
on this study, it is certainly not IL-12. A recently published
paper (J Exp Med 2004, 199: 125–30) reports increased
expression of IL-23, a cytokine which shares the p40 chain
and thus is related to IL-12, in psoriatic lesions. The authors
of this report suggest that IL-23 may play a more dominant
role than IL-12 in psoriasis. We will see. In any case, the
cytokine hunting continues.
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